Chest Pain Drug Ranolazine Falls Short in Preventing First Episode of Ventricular Arrhythmia or Death

A trial of more than 1,000 patients with implantable cardioverter defibrillators found that the chest pain drug ranolazine was safe but didn ’t decrease the likelihood of the first occurrence of ventricular arrhythmias or death in this high-risk population.
Source: University of Rochester Medical Center Press Releases - Category: Universities & Medical Training Authors: Source Type: news